Presentation is loading. Please wait.

Presentation is loading. Please wait.

Genetic Modified Cell Therapy for Amyotrophic Lateral Sclerosis (ALS) Tianyi Cai PBIO-4500 12/02/2014.

Similar presentations


Presentation on theme: "Genetic Modified Cell Therapy for Amyotrophic Lateral Sclerosis (ALS) Tianyi Cai PBIO-4500 12/02/2014."— Presentation transcript:

1 Genetic Modified Cell Therapy for Amyotrophic Lateral Sclerosis (ALS) Tianyi Cai PBIO /02/2014

2 Overview and Futures of ALS A fatal neurodegenerative disorder causes death of motor neurons Patients develop paralysis rapidly and die due to respiratory insufficiency in 3-5 years after diagnosis 10% ALS are familial (fALS) 20% of fALS cases are linked to mutation for SOD1 (over-expressed) allele containing Gly93. Traditional pharmacological therapies have largely failed so far

3 Design and Mechanism of the Experiment The researchers found that glucagon-like peptide 1 (GLP-1) exhibits anti- oxidation and is neuroprotective against excitotoxicity. To avoid systemic administration, the researchers decided to deliver GLP-1 directly into the central neurvous system. Researchers investigative tested an encapsulated cell line which can produce GLP-1 to replace an osmotic minipump which may cause more complications. Scientists modified a mesenchymal stromal cell (MSC) line to produce GLP-1. An encapsulated GM MSC is intracerebroventricular injected in experimental animals to test the results.

4 Materials and Methods Experimental animals – G93A transgenetic familial ALS mice (Figure 1.) Cell Line and Alginate microcapsules – Cell lines: hMSC cell line was immortalized by transduction with the human Telomarase Reverse Transcriptase (hTERT) gene. Then, cells are transfected with a plasmid vector encoding GLP-1 fusion gene. – Microcapsules: Cells are embedded in a 160 μm diameter spherical alginate matrix. One matrix contains about 94 cells. (Figure 2.)

5 Figure 1. Analysis of post-mortem brain tissue at day 110 of SOD1 (G93A) mice. Knippenberg S, Thau N, Dengler R, Brinker T, et al. (2012) Intracerebroventricular Injection of Encapsulated Human Mesenchymal Cells Producing Glucagon-Like Peptide 1 Prolongs Survival in a Mouse Model of ALS. PLoS ONE 7(6): e doi: /journal.pone

6 Figure 2. Alginate encapsulated GLP-1 producing mesenchymal cells. Knippenberg S, Thau N, Dengler R, Brinker T, et al. (2012) Intracerebroventricular Injection of Encapsulated Human Mesenchymal Cells Producing Glucagon-Like Peptide 1 Prolongs Survival in a Mouse Model of ALS. PLoS ONE 7(6): e doi: /journal.pone

7 Materials and Methods Method – Drill a 1.4 mm hole on the head of each mouse. – Inject microcapsules which were treated by the cell solution into brain through the hole. Treatment group and vehicle control group – One group of mice was treated by microcapsules contains MSC which can produce GLP-1. – The other group mice was treated by empty microcapsules.

8 Result Survival Study (Figure 3, Figure 4) – General conditional – Survival percentage – Weight – Rotarod performance – Step length analysis – Runtime analysis Histological analysis

9 Figure 3. Effects of GLP-1 treatment on survival times, general condition and weight measurements. Knippenberg S, Thau N, Dengler R, Brinker T, et al. (2012) Intracerebroventricular Injection of Encapsulated Human Mesenchymal Cells Producing Glucagon-Like Peptide 1 Prolongs Survival in a Mouse Model of ALS. PLoS ONE 7(6): e doi: /journal.pone

10 Figure 4. Effects of GLP-1 treatment on rotarod performance and footprint analyses. Knippenberg S, Thau N, Dengler R, Brinker T, et al. (2012) Intracerebroventricular Injection of Encapsulated Human Mesenchymal Cells Producing Glucagon-Like Peptide 1 Prolongs Survival in a Mouse Model of ALS. PLoS ONE 7(6): e doi: /journal.pone

11 Figure 5. Immunhistological analysis of MAP2 in spinal cord tissue of SOD1 (G93A) mice. Staining against microtubule associated protein 2 was stronger in animals treated with GLP-1 MSC (right) compared to control group (Left ).

12 Conclusion According to the data, we can conclude that intracerebroventricular injection of encapsulated hMSC-GLP1 exhibits neuroprotective potential in SOD1- G93A mice.

13 Discussion Advantages – Compare to the only medicine, Riluzole, hMSC-GLP1 delays the disease onset and weight loss. – This cell therapy has less side effects compare to the other therapies. Limitation – Has to be treated before the disease onset. – Surgery may cause other systemic inflammation.

14 Reference Knippenberg S, Thau N, Dengler R, Brinker T, Petris; Intracerebroventricular injection of encapsulated human mesenchymal cells producing glucagon-like peptide 1 prolong survival in a mouse model of ALS. PLoS One, Lewis C, Suzuki M; Therapeutic applications of mesenchymal stem cells for amyotrophic lateral sclerosis. Stem Cell Research & Therapy, 2014, 5. Keifer O, O’Connor D, Boulis N; Gene and protein therapies utilizing VEGF for ALS. Pharmacology & Therapeutics, 2014, 141. Gao A, Peng Y, Deng Y, Qing H; Potential therapeutic applications of differentiated inducedpluripotent stem cells in the treatment of neurodegenerative diseases. Neuroscience, 2013, 228.

15 Thank you!


Download ppt "Genetic Modified Cell Therapy for Amyotrophic Lateral Sclerosis (ALS) Tianyi Cai PBIO-4500 12/02/2014."

Similar presentations


Ads by Google